BioLineRx (BLRX) Enters 2.7M ADS DIrect Placement
Tweet Send to a Friend
Up)
BioLineRx Ltd. (Nasdaq: BLRX) has entered into a definitive agreement with leading healthcare investor OrbiMed Israel Partners Limited Partnership, an affiliate of OrbiMed Advisors LLC (“OrbiMed”), pursuant to which OrbiMed has agreed to purchase 2,666,667 American Depositary Shares (“ADSs”), each representing ten (10) of its Ordinary Shares, and 1,600,000 warrants to purchase an additional 1,600,000 ADSs, at a unit price of $3.00. The warrants have an exercise price of $3.94 per warrant and are exercisable for a term of five years.
The Company will receive proceeds of $8,000,000, before deducting customary offering expenses, which it expects to use to fund clinical trials and for working capital and general corporate purposes.
The offering is expected to close on or about February 11, 2013, subject to satisfaction of customary closing conditions.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The Company will receive proceeds of $8,000,000, before deducting customary offering expenses, which it expects to use to fund clinical trials and for working capital and general corporate purposes.
The offering is expected to close on or about February 11, 2013, subject to satisfaction of customary closing conditions.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Bloomin' Brands (BLMN) Prices 19M Common Stock Secondary Offering
- NPS Pharmaceuticals (NPSP) Prices 6M Common Stock Offering
- LRAD Corp, (LRAD), Iroquois Master Fund Enter Settlement
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
OrbiMed Advisors
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
